Abstract:Highlights • This study highlights the benefits of integrating microneedle (MN) technologies with the nanoemulsion (NE) system represents a promising approach to enhance the transdermal delivery of estradiol valerate (E2V), a hydrophobic drug with a Log P of 6.62. • E2V-NE formulations and core-shell dissolving microneedles (CS-dMNs) were developed utilizing a computational design strategy. • Developed self-administered E2V-NE-loaded CS-dMNs offering a convenient platform for achieving long-acting and controlled hormone levels in clinical response dosages. Estradiol valerate (E2V) is a hormone utilized for estrogen replacement therapy. Nonetheless, its application in pharmaceutical formulations has been limited due to its poor solubility in water and suboptimal efficacy for transdermal drug delivery. Hence, the combination of nanoemulsions (NEs) with core-shell dissolving microneedles (CS-dMNs), which encase the drug, represents a promising approach to enhance transdermal drug delivery while ensuring controlled release. This study aimed to develop E2V-NE-loaded CS-dMNs for achieving controlled transdermal release of E2V. The E2V-NEs were formulated and evaluated for parameters including droplet size, polydispersity index (PDI), and zeta potential. Subsequently, these E2V-NEs were integrated into the core of CS-dMNs. The physical and mechanical properties of E2V-NE-loaded CS-dMNs were evaluated, along with parameters such as detachment time, drug content, in vitro and in vivo skin permeation, and safety. The results indicated that E2V-NE-loaded CS-dMNs exhibited favorable physical and mechanical characteristics, enabling easy self-administration with patch detachment after 30 min, while ensuring controlled drug release from the core of dMNs. The E2V content in CS-dMNs was determined to be 0.76 ± 0.15 mg/patch. Furthermore, in vitro and in vivo skin permeation studies demonstrated a synergistic effect between NEs and MNs, achieving therapeutic drug levels sustained over a week (368.54 ± 67.93 μg/mL in in vitro and 697.45 ± 270.10 pg/mL in in vivo), with no indications of infection and complete skin healing observed within 8 h. Consequently, E2V-NE-loaded CS-dMNs present a promising alternative for achieving sustained and controlled hormone levels conveniently. Graphical abstract Download : Download high-res image (242KB) Download : Download full-size image

Sustained estradiol valerate delivery by microneedles: A new effective platform to construct estrogen-dependent tumor model

Sustained delivery of 17β-estradiol by human amniotic extracellular matrix (HAECM) scaffold integrated with PLGA microspheres for endometrium regeneration.

Computer-aided design and optimization of estradiol valerate nanoemulsion-loaded core-shell microneedle patches for controlled release transdermal drug delivery

Intradermal Implantable PLGA Microneedles for Etonogestrel Sustained Release

Design, optimization, and evaluation for a long-time-released transdermal microneedle delivery system containing estradiol

Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer

Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy

Multimicrochannel Microneedle Microporation Platform for Enhanced Intracellular Drug Delivery

Locally administered nanosuspension increases delivery of estradiol for the treatment of vaginal atrophy in mice

Microchip Based Isolation and Drug Delivery of Patient-Derived Extracellular Vesicles Against Their Homologous Tumor

Preparation and Cytotoxicity of Poly (Dl-Lactide-co-glycolide) Microspheres Encapsulating 2-Methoxyestradiol

Design and Validation of PEG-Derivatized Vitamin E Copolymer for Drug Delivery into Breast Cancer.

Ex vivo evaluation of a microneedle array device for transdermal application

PEGDA/PVP Microneedles with Tailorable Matrix Constitutions for Controllable Transdermal Drug Delivery

Tumor-derived extracellular vesicle drug delivery system for chemo-photothermal-immune combination cancer treatment

Engineered mesenchymal stem cell-derived extracellular vesicles constitute a versatile platform for targeted drug delivery

Transdermal Delivery of Therapeutics Through Dissolvable Gelatin/sucrose Films Coated on PEGDA Microneedle Arrays with Improved Skin Permeability

Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers

In vitro and in vivo investigation of a novel two-phase delivery system of 2-methoxyestradiol liposomes hydrogel

Phospholipid-Anchored Ligand Conjugation on Extracellular Vesicles for Enhanced Cancer Targeting

In Vivocontrolled Release and Prolonged Antitumor Effects of 2-Methoxyestradiol Solid Lipid Nanoparticles Incorporated into a Thermosensitive Hydrogel